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Objectives: The current prevalence of Diabetes Mellitus (DM) in Slovakia ranges 
in about 340000 cases. Insulin therapy is realised in the group about 44000 patients, 
including about 21000 men and 23000 women in the patients older than 19 years. 
Till now in the Czech Republic and in the Slovak Republic there was not realised the 
study oriented on the quality of life (QolL) in relation to young people with DM type 
I, treated by insulin pens or insulin pumps. MethOds: 102 patients with type 1 dia-
betes mellitus aged from 18 to 35 attending diabetes centres and clinics in Brno and 
its surroundings were studied. The method of quantitative research was used to col-
lect the data obtained by standardized questionnaire ADDQoL and DTSQs with the 
confirmed copyright. Results: The general value of QoL was 5.65 on the numeric 
scale from 0 to 10 (0 for the worst results, 10 for the best results). The positive sta-
tistical significance with “p” lesser than 0.05 was find out comparing insulin pump 
vs insulin pen: hobby and free time physical activities, family life, recommendation 
treatment by pump, and satisfaction with the form of treatment and continuing 
of the treatment. The evaluation of these categories has no statistical significance: 
too high level of glucose in the blood, too small level of glucose in the blood, the 
adaptation to the treatment, and the understanding to the illness. cOnclusiOns: 
Statistical evaluation of the hypotheses confirmed a better quality of life in patients 
with insulin pump. On the contrary, the difference in perception of the quality of life 
between the sexes was not proved. Our research confirmed that the insulin pump 
is a modern way of compensation and has a positive impact on the quality of life 
in young patients with diabetes.
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IS THE RUlE Of HAlvES APPlICABlE IN DIABETES TyPE 2? EvIDENCE fROm 
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National School of Public Health, Athens, Greece
Objectives: The “rule of halves” (ROH) applies in most common chronic disorders 
and suggests that half of the patients are undiagnosed, half of those diagnosed are 
not treated, and half of those treated are not controlled. The aim of the present 
study was to examine whether the ROH is applicable in the case of Diabetes type 2 
in Greece. MethOds: Physicians who monitor patients with type 2 diabetes were 
invited to participate and complete the online version of a purpose-made question-
naire during a specified time period. An invitation was sent to the national associa-
tions of general practitioners (GPs), diabetologists and endocrinologists. The study 
took place between April and May 2014. Fully completed questionnaires were included 
in the analysis. Data analysis was conducted using STATA 9. Results: 176 physicians 
completed the questionnaire of whom 68.7% were men. Mean age was 47.8 years. The 
majority were internists and GPs (38.3% and 32.7%, respectively). Physicians estimated 
that in Greece 62% of those diagnosed with diabetes type 2 receive some kind of treat-
ment (lifestyle or pharmacotherapy). 59.3% of those diagnosed will present at least 
one complication because of the disease. Less than half (43.3%) of those treated are 
controlled and achieve treatment targets (HbA1c≤ 7%). Of those not controlled, 73.3% 
will present at least one complication because of diabetes type 2. cOnclusiOns: 
According to our findings, in Greece more than half of the diagnosed patients with 
diabetes type 2 receive treatment in a regular basis. However, less than half achieve 
treatment targets and manage to stay controlled. Emphasis should be given in self-
management, patient education and policies raising awareness for the early detec-
tion and management of diabetes type 2 in order to increase controlled patients and 
decrease the incidence of complications due to the disease.
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PHySICIANS ESTImATION REGARDING THE ImPACT Of RECESSION ON PATIENT 
ADHERENCE TO TREATmENT IN DIABETES TyPE 2 IN GREECE
Tsiantou V., Zavras D., Karampli E., Athanasakis K., Pavi E., Kyriopoulos J.
National School of Public Health, Athens, Greece
Objectives: Adherence to treatment plan and lifestyle advice is crucial for good 
health outcomes in diabetic patients. Given that Greece in the last years faces an 
unprecedented economic crisis which affects all sectors of economic and social life, 
the aim of the present study was to examine whether recession, austerity measures 
and implemented health policies had an impact on patient adherence to treatment 
in Diabetes type 2 (dt2) in Greece. MethOds: A questionnaire was developed for 
the purpose of the study. Only Physicians who monitor patients with dt2 (general 
practitioners (GPs), diabetologists and endocrinologists) were invited to participate in 
the study and complete the online version of a purpose-made questionnaire during a 
specified time period. Physicians were recruited through their national associations. 
The study took place between April and May 2014. Results: Of the 176 physicians 
completing the questionnaire, 68.7% were men. Mean age was 47.8 years. The majority 
were internists (38.3%) and GPs (32,7%). Physicians estimated that during the previ-
ous year 22.9% of their patients had to quit or modify their treatment plan due to 
economic reasons. A somewhat higher percentage (26.9%) was found regarding the 
modification of the dietary habits during the previous year due to economic reasons 
which led to negative health outcomes. According to the participating physicians the 
main reasons for which patients modified or quitted their treatment were the higher 
copayments for pharmaceuticals, loss of insurance coverage and barriers of access 
to a physician in order to prescribe their medicines. cOnclusiOns: Recession and 
recent health policies had a negative impact on patients’ adherence to treatment 
leading to poor adherence almost a quarter of patients with dt2, based on the expe-
rience of physicians. Equally critical is the fact that patients were forced to modify 
their dietary habits.
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2 diabetes. MethOds: This was a retrospective cohort study that identified the DD 
adults with type 2 diabetes from the MarketScan® Multi-State Medicaid Database. 
Enrollees aged 18-64 years who received new anti-diabetic medications from January 1, 
2004 and December 31, 2006 were included. An index diagnosis date was assigned to 
each patient and adults with a continuous enrollment for at least 12 months were 
included. Multivariate negative binomial regression was used to measure the rate of 
change in type 2 diabetes related health care utilization (inpatient, outpatient and 
emergency department visits) in DD patients. Multivariate linear regression with log-
transformation was used to determine type 2 diabetes related health care costs in DD 
Medicaid enrollees. Results: The study population comprised of 1529 patients. After 
controlling for all the covariates, compared to DD Caucasians, DD African Americans 
were more likely to have type diabetes related inpatient (OR= 1.71; 95% CI, 1.02-2.85) 
and emergency department visits (OR, 1.67; 95% CI, 1.02-2.73). After holding all the 
other covariates constant, among DD patients with type 2 diabetes, compared to 
Caucasians, African American patients had 23% significantly higher medication 
costs, 26% significantly higher medical costs and 21% significantly higher overall 
costs respectively. cOnclusiOns: Racial disparities exist in health care utilization in 
DD Medicaid patients with type 2 diabetes. Access to culturally competent health care 
providers, providers who accept Medicaid patients and continuous care can reduce 
inpatient visits and emergency room visits in racial minorities.
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Hypoglycemia (Hypo) is a common adverse effect of type 2 diabetes (T2D) therapy. 
Oral antidiabetic (OAD) agents differ in their propensity to cause Hypo. Hypo has 
a negative impact on health care resources and quality of life (QoL) and can affect 
compliance and T2D control. Objectives: To estimate the impact of different 
OADs on Hypo prevalence and on the QoL of T2D patients in Greece. MethOds: 
A cross-sectional epidemiological study was conducted in 6631 patients with T2D. 
Hypo events with different treatment regimens, T2D control rates and QoL were 
assessed. Hypo episodes were defined as laboratory-confirmed (< 70 mg/dl) symp-
tomatic events. QoL was measured using the patient-administered ADDQoL-19 
questionnaire. Diabetes control was defined as Hb1Ac ≤ 7%. Results: Mean age 
was 60 and mean T2D duration 10 years. 59% of patients had HbA1c > 7%; 20.4% had 
Hypo. Most patients (82%) were on combination therapies, while 14.5% were on oral 
monotherapy and the remaining were on insulin or GLP-1 analog treatment. The 
overall QoL in the three OAD monotherapy groups [biguanides, DPP4is and sulfony-
lureas (SUs)] were not statistically significant between groups, regardless of Hypo 
status. However, patients treated with biguanide or DPP4i monotherapy had lower 
rates of Hypo vs. patients on SU monotherapy (p≤ 0.001) and QoL in Hypo patients 
treated with biguanides or DPP-4is was better compared to SUs (p< 0.001). Similarly, 
more patients on biguanides and DPP4i monotherapies achieved HbA1c ≤ 7% than 
on SU (p≤ 0.001). Patients receiving combinations of biguanides with DPP4is vs. 
biguanides with SUs had significantly less Hypo (p≤ 0.001), better diabetes control 
(respectively; p≤ 0.001) and better QoL (p≤ 0.05). cOnclusiOns: Biguanides, DPP4is 
and their combinations are associated with lower rates of Hypo, better QoL and 
T2D control, compared with SUs alone or in combination with biguanides. In T2D, 
treatment should attain good glycemic control without debilitating hypoglycemic 
episodes, which compromise patients’ QoL.
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QUAlITy Of lIfE IN DIABETIC PATIENTS
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Objectives: Comparison of the changes in QoL of diabetic patients after phar-
maceutical cognitive service with SF-6D. MethOds: Tree step methodology was 
created and applied towards the patients with type 1 and type 2 diabetes. On first 
the QoL of 146 diabetic patients was assessed with the Bulgarian version of SF-6D. 
Then educational program for the diabetic patients was developed and applied 
during the day of their visits in community pharmacy from June to September 2013. 
At the end the changes in the QoL after the pharmaceutical cognitive service was 
assessed in the group of 24 patients. Results: The mean age of patients included 
in the first step was 57.39 years (SD 17.087; 95%CI 54.60-60.19). 76% of them were 
with type 2 diabetes and 73% suffers from diabetes complications. The mean SF-6D 
score was 0.629 (SD 0.289; 95%CI 0.58-0.68). After the pharmacy program the type 
2 diabetic patients showed better quality of life index 0.7133 that was 10% higher 
than the initial score 0.6089. In the patients with type 1 diabetes the improvement of 
QoL score is with 3 %. The patients were with mean SF-6D scores: 0.667 on the first 
visit in the pharmacy and 0.690 after the educational service. cOnclusiOns: The 
study suggests the SF-6D is a valuable tool for QoL assessment of diabetes patients 
in Bulgaria. It also shows that SF-6D could be used for pharmacy program evalua-
tion in diabetes patients. Regarding the pharmaceutical cognitive service in diabetic 
patients is evident that they have a potential to improve the QoL in patients with 
diabetes mellitus and their impact could be measured with SF-6D.
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WHICH NEWly-DIAGNOSED DIABETICS SHOUlD RECEIvE DIETARy 
COUNSElING SERvICES? ESTImATING INDIvIDUAlIzED TREATmENT 
AllOCATIONS THAT OPTImIzE COST-EffECTIvENESS IN REAl-WORlD DATA
Signorovitch J.1, Betts K.A.1, Meng X.1, Zhuo Y.2, Wu E.Q.1, Shi L.3
1Analysis Group, Inc., Boston, MA, USA, 2MIT, Cambridge, MA, USA, 3Tulane University, New 
Orleans, LA, USA
Objectives: All people with type 2 diabetes should receive dietary advice. Some 
patients may benefit from additional dietary counseling. This study used recently 
developed statistical methods to estimate the efficiency frontier for individualized 
allocation of dietary counseling services. I. e., for each level of total health care 
expenditure, we estimate the individualized allocation of services that maximizes 
clinical benefit in the population. MethOds: People newly diagnosed with type 2 
diabetes were identified retrospectively from electronic health records and classified 
as receiving vs. not receiving dietary counseling. An individualized effectiveness 
score for achievement of HbA1c < 7% with vs. without counseling was estimated 
using multivariable logistic regression. Demographics, vitals, comorbidities and 
lab values served as candidate predictors. Prediction models were validated in a 
held-out sample. The efficiency frontier was estimated as the convex hull of the 
set of HbA1c control rates and total costs achievable by allocation of dietary coun-
seling based on the effectiveness score. Results: Among 11,819 patients newly 
diagnosed with type 2 diabetes, 22% received dietary counseling and 74% achieved 
HbA1c control. Greater HbA1c, body mass index and age at the time of diagnosis 
were associated with greater effectiveness of dietary counseling. Allocation of all 
newly diagnosed diabetics to dietary counseling was estimated to increase the 
rate of HbA1c control to 80% at a cost of 56 USD per patient vs. current practice. An 
efficient allocation rule (counseling only the 55% of patients predicted to benefit 
most) achieved the same 80% control rate with an incremental cost of 6 USD per 
patient. cOnclusiOns: Retrospective analysis of real-world data identified oppor-
tunities to improve diabetes outcomes vs. current practice with minimal expense 
through individualized allocation of dietary counseling. This result warrants valida-
tion in separate data. The analytical methods warrant broader use to investigate 
efficient allocation of treatments.
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CHRONIC CARE mANAGEmENT
Gajdos O., Jurickova I.
Czech Technical University in Prague, Kladno, Czech Republic
Objectives: Chronic illness is a prolonging health defect, which is causing a big 
use of financial means for its medical care. These means are not being coordinated 
and used effectively. The aim of this study was to suggest a management care 
system of the chronically ill in the Czech Republic, which should increase the 
quality of medical care and decrease the costs of it. MethOds: There was chosen 
an appropriate diagnosis and concept for the management care, which were based 
on analysis of the current state. The type 2 diabetes mellitus was chosen as an 
appropriate chronic illness and for the management care concept was chosen 
Patient-Centered Medical Home.. The randomized selection of 100 patients was 
made in ordinary diabetes ambulance. The cost of illness was counted from the 
direct costs from the perspective of the society, of the payer and of the patient. 
The cost effectiveness analysis, which was comparing a standard treatment and 
chosen concept, was based on randomized selection, studies of Patient-Centered 
Medical Home and recommended standards of professional society. There were 
also used methods of value engineering especially Saaty matrix and multi-cri-
teria decision making, mainly TOPSIS method for setting the scales of criteria 
and effect. Results: The average costs of one patient are from the perspective 
of the society 29 531 CZK, the payer 20 976 CZK and of the patient 9 196 CZK. The 
Patient–Centered Medical Home has taken the first place in comparison with a 
standard treatment, which was based on the cost of effectiveness analysis. The 
payer will obtain a 25.7x10-5 of the effect for Patient-Centered Medical Home 
according a spent monetary unit. cOnclusiOns: The costs of the chosen concept 
can be more effective. The concept would provide greater prevention, quality and 
coordinated care and can be used for other chronic diseases.
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A COmPARATIvE ANAlySIS ON THE REImBURSEmENT STATUS Of SENSOR 
AUGmENTED PUmP THERAPy IN TURkEy AND OTHER SElECTED COUNTRIES
Seyhun O., Erdol S., Can H., Erdogan E.
Medtronic, Inc., Istanbul, Turkey
Objectives: Sensor augmented therapy (SAP) with automated insulin suspen-
sion is the most advanced technology for the treatment of severe and moderate 
hypoglisemia in patients with type 1 diabetes mellitus. In order to sustain a bet-
ter uptake of sensor augmented therapy for patients, it is crucial for this tech-
nology to be included in the reimbursement scheme of Turkey and in the other 
countries. Thus, we aimed to study and analyze reimbursement status of this 
technology in Turkey and across other selected countries of Western Asia, North 
America and Western Pacific. MethOds: Mainly official web resources such as 
health authority web pages, direct contact with authority responsibles and pub-
lished articles on SAP are utilized. Results: Most of the countries examined 
have either reimbursement or limited status of SAP. European countries such 
as Ireland, The Netherlands, Sweden, Estonia, Czech Republic; Israel in Western 
Asia, Japan in Western Pacific and USA are the ones where this technology is reim-
bursed mainly for patients with Type 1 Diabetes. Within these selected countries, 
Turkey has a position of having reasonably well defined reimbursement status 
for SAP despite insufficient number of sensors reimbursed - 2 sensors instead 
of 5 sensors a month; which potentially causes an incomplete therapy for the 
patients. cOnclusiOns: Despite the operational hurdles and insufficient number 
of sensors reimbursed per patient in Turkey, the country still stands as a success-
ful example of reimbursement practice, by making this technology available for 
the indicated patients.
1The Johns Hopkins Hospital, Baltimore, MD, USA, 2The Johns Hopkins Medical Institutions, 
Baltimore, MD, USA
Objectives: A pharmacy-based inpatient diabetes management program was 
evaluated to determine if improved glycemic control could be achieved in a gen-
eral medicine patient population. MethOds: A retrospective chart review of 151 
patients with blood glucose (BG) values outside the range 70-180 mg/dL was con-
ducted. Observations for the baseline group (n= 84) were derived from July 2010 and 
for the intervention group (n= 67) in October 2010. The odds of poor glycemic control 
for patients in the intervention versus baseline groups were assessed by multi-
variate generalized estimating equations. These methods were also used to assess 
patient characteristics associated with poor glycemic control. Results: Across all 
patients, no evidence was observed indicating the pharmacy program decreased the 
proportion of days spent out of the targeted blood glucose range [70-180 mg/dL: OR 
0.91 (95% CI: 0.83 – 1.02); 70-250 mg/dL: OR 1.03 (95% CI: 0.88 – 1.24)]. However, the 
subgroup of patients whose admission blood glucose was less than 200 mg/dL (55% 
of intervention group) experienced a significant reduction in days out of range for 
both ranges [70-180 mg/dL (OR: 0.72, 95% CI: 0.61– 0.88) and 70-250 mg/dL (OR: 0.5, 
95% CI: 0.33 – 0.71)]. No improvement in glycemic control was observed in patients 
with an admission BG 200 mg/dL or greater. These patients had more disease- and 
social-related factors associated with poor glycemic control. cOnclusiOns: A sub-
population, patients whose admission glucose was less than 200 mg/dL, experienced 
improvement in glycemic control in the pharmacy-based program. The remaining 
patients were generally more complicated from a disease-state and social perspec-
tive and experienced no improvement. These patients may require a more intense, 
multi-disciplinary approach that is better matched to the constellation of factors 
responsible for their condition.
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COmPlIANCE TO HEmOGlOBIN A1C TESTING RECOmmENDATIONS fOllOWING 
INITIAl DIABETES DIAGNOSIS
Palmer L.A.1, Hansen L.G.2
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Objectives: The hemoglobin A1c test (HbA1c) is the favored measure of gly-
cemic control for patients with diabetes. Compliance to recommended testing 
continues to be a challenge. The current analysis evaluates how compliance to 
HbA1c testing varies based on initial HbA1c results. MethOds: Newly diagnosed 
patients with Type II diabetes were identified using the Truven Health MarketScan 
Lab Database (1/1/2010-10/31/2013). Continuous eligibility for the 6 months prior 
and 12 months following diagnosis were required for study inclusion. Patient 
cohorts were created based on first HbA1c test value (< 7.0% [controlled], ≥ 7.0% 
[uncontrolled]). Presence of a subsequent HbA1c test, including test result and 
time to test, were evaluated for these cohorts. Results: A total of 133,011 
patients met the study inclusion criteria; approximately 40% had evidence of 
an initial HbA1c test (n= 33,616 with HbA1c < 7.0%; n= 19,033 with HbA1c ≥ 7.0%). 
Approximately 64% (n= 21,497) of controlled patients had a subsequent HbA1c 
test (86% with HbA1c < 7.0%, 14% with HbA1c ≥ 7.0%); 91% (n= 17,344) of uncon-
trolled patients had a subsequent HbA1c test (36% with HbA1c < 7.0%, 64% with 
HbA1c ≥ 7.0%). Mean times (in days [d]) to subsequent HbA1c test (and result) 
were as follows: Among initially controlled patients: 231d (controlled) and 370d 
(uncontrolled); among initially uncontrolled patients: 238d (controlled) and 212d 
(uncontrolled). Mean time to HbA1c test was significantly longer for controlled 
patients with HbA1c ≥ 7.0% for subsequent test relative to controlled patients 
with HbA1c < 7.0% and to uncontrolled patients with HbA1c ≥ 7.0% for subsequent 
tests. cOnclusiOns: Compliance to recommended timing for HbA1c testing 
is suboptimal in the majority of patients regardless of initial glycemic control. 
Importance of regular HbA1c evaluation should continue to be part of patient 
education – particular for patients who may initial appear to have favorable gly-
cemic control.
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Objectives: The Syreon health economic model was developed to predict long 
term effects of screening, treatment and control of type 2 diabetes, by taking into 
account baseline patient characteristics, history of complications, changes in physi-
ological parameters, diabetes treatment and management strategies and screening 
programs. The aim of this analysis was to assess the cost-effectiveness of intro-
ducing a national public health program in Hungary to improve diabetes patient’s 
adherence in comparison to not introducing the program. MethOds: According 
to the guideline of the Hungarian National Diabetes Association, the target HbA1c 
level is below 7%, except for special cases, where it is 8% or less. Without an organ-
ized patient education program 45% of the patients with known diabetes have 
higher than the target HbA1c level. In the studied scenario, the education program 
improves the patient adherence by 30% and increases the proportion of diabetic 
patients achieving the target HbA1c level to 72%. Patients reaching the target HbA1c 
level fully enjoy the benefits of efficient treatment. Non-adherent patients have 
higher HbA1c levels and face higher risk for diabetes-related complications, e. g. 
stroke, neuropathy or retinopathy. Results: The Syreon diabetes model is capable 
of analyzing the consequences of introducing the adherence program for patients 
with diagnosed diabetes. The results of the cost-effectiveness analysis were sensi-
tive to the starting age of the target population and the effectiveness of the training 
program. cOnclusiOns: Organized patient education program was predicted to 
be cost-effective compared with no program in Hungary. The education program 
contributes to better patient adherence resulting in better health and less disease 
related complications.
